Substance Use Disorder: Molecular Basis and Therapeutics

A special issue of NeuroSci (ISSN 2673-4087).

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 3913

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23298, USA
Interests: medicinal chemistry; structure-based drug design; structure biology; pharmacology; chemical biology

Special Issue Information

Dear Colleagues, 

Neuropsychiatric conditions significantly contribute towards global disease burden, and substance use disorders (SUDs) make up the second-largest proportion of this burden after depression. SUDs describe both the use of illegal or illicit substances and the misuse of legal substances such as alcohol, nicotine, or prescription drugs. SUD or addiction is a complex polygenic psychiatric condition involving various brain regions, proteins, and physiological effects encompassing diverse etiologies. The similarity of the pharmacological and behavioral effects of structurally diverse drugs may be explained by the fact that each drug, despite its many distinct actions in the brain, converges to produce some common outcomes by activating the reward circuits in the brain. An ever-increasing number of neuroscientists are searching for clues regarding the molecular determinants of addictive behavior, and considerable progress has been made in identifying the molecular and cellular mechanisms underlying addictive behavior, including dependence, tolerance, and withdrawal.

This Special Issue focuses on understanding the molecular and cellular mechanisms underlying SUDs. We welcome reviews, short communications, and original research articles that shed light on the neurological effects of substance abuse as well as novel psychosocial and therapeutic strategies for alcohol, cannabis, cocaine, opiate, and polysubstance abuse and dependence treatments.

Dr. Piyusha P. Pagare
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. NeuroSci is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • opioid use disorder
  • alcohol
  • drug abuse
  • nicotine
  • marijuana
  • stimulants
  • hallucinogens
  • addiction
  • dependence
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 1664 KiB  
Review
Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them
by Megan R. Greener and Sarah J. Storr
NeuroSci 2022, 3(3), 494-509; https://doi.org/10.3390/neurosci3030035 - 25 Aug 2022
Cited by 3 | Viewed by 3160
Abstract
We are amidst a global addiction crisis, yet stigmas surrounding addiction counterintuitively prevail. Understanding and appreciating the neurobiology of addiction is essential to dissolve this stigma and for the development of new pharmacological agents to improve upon currently narrow therapeutic options. This review [...] Read more.
We are amidst a global addiction crisis, yet stigmas surrounding addiction counterintuitively prevail. Understanding and appreciating the neurobiology of addiction is essential to dissolve this stigma and for the development of new pharmacological agents to improve upon currently narrow therapeutic options. This review highlights this and evaluates dopamine-and-cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) as a potential target to treat various forms of substance abuse. Despite the proven involvement of DARPP-32 in addiction pathophysiology, no robust investigations into compounds that could pharmacologically modulate it have been carried out. Agents capable of altering DARPP-32 signalling in this way could prevent or reverse drug abuse and improve upon currently substandard treatment options. Full article
(This article belongs to the Special Issue Substance Use Disorder: Molecular Basis and Therapeutics)
Show Figures

Figure 1

Back to TopTop